Monjuvi
FDA Approves Monjuvi for Relapsed or Refractory Follicular Lymphoma
The FDA approved tafasitamab (Monjuvi, Incyte) with lenalidomide and rituximab for adults with relapsed or ...
JUNE 20, 2025
Addition of Second Monoclonal Antibody Improves Outcomes of Follicular Lymphoma
When tafasitamab (Monjuvi, Incyte), an anti-CD19 monoclonal antibody, is added to a regimen that includes the ...
DECEMBER 18, 2024
FDA Approves Monjuvi Plus Revlimid for DLBCL
The FDA granted accelerated approval to tafasitamab-cxix (Monjuvi, MorphoSys US/Incyte) in combination with ...
AUGUST 7, 2020
Load more